pelareorep
pelareorep: developed by 1 company · 3 clinical trials tracked.
pelareorep evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could pelareorep → ONCY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ONCOLYTICS BIOTECH INC (ONCY) Ras-mutated Metastatic Colorectal Cancer; Anal Cancer Metast… | Phase 1/Phase 2 |
Clinical Trials (3)
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Primary endpoint: Overall Response Rate (ORR)
A Phase 1 / 2 Multiple-indication Biomarker, Safety, and Efficacy Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Primary endpoint: Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5
IRENE Study: Phase 2 Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Negative Breast Cancer
Primary endpoint: Objective response rate (ORR)
Frequently asked questions
Who is developing pelareorep?
pelareorep is being developed by ONCOLYTICS BIOTECH INC.
How many clinical trials involve pelareorep?
BioSniper tracks 3 clinical trials involving pelareorep.